Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma

Y. Fujita, Tomonori Nakamura, Tohru Aomori, H. Nishiba, T. Shinozaki, T. Yanagawa, K. Takagishi, H. Watanabe, Y. Okada, K. Nakamura, R. Horiuchi, Koujirou Yamamoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Individualization of high-dose methotrexate (MTX) dosing is important to achieve therapeutic levels (700-1,000 μM) for osteosarcoma. Therefore we developed a pharmacokinetically (PK) individualized dosage regimen to maintain MTX concentrations of 700 μM (1 h bolus followed by 5 h maintenance infusion) and evaluated its safety and efficacy. Loading and maintenance doses were calculated by the PK parameters based on 2-compartment model analysis. Thirty-two courses of chemotherapy were performed in 9 patients with osteosarcoma. The maximum concentrations during maintenance infusion in 31 courses (97%) were above 700 μM. Only 1 patient developed severe hepatotoxicity as adverse effect. Total body clearance of MTX decreased in 4 patients when weekly MTX chemotherapy was performed for 3 consecutive weeks. Although the clearance was changed, the average MTX concentrations were maintained at about 700 μM by the PK individualization. The 5-year survival rate was 77.8% (7 of 9 patients), and all of them have survived for more than 9 years. This PK individualization is safe and useful for tailoring high-dose MTX therapy to achieve therapeutic levels.

Original languageEnglish
Pages (from-to)186-190
Number of pages5
JournalJournal of Chemotherapy
Volume22
Issue number3
Publication statusPublished - 2010 Jun
Externally publishedYes

Fingerprint

Osteosarcoma
Methotrexate
Pharmacokinetics
Drug Therapy
Therapeutics
Maintenance
Survival Rate
Safety

Keywords

  • 5-Year survival rate
  • Methotrexate
  • Osteosarcoma
  • Pharmacokinetic individualization

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Cite this

Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma. / Fujita, Y.; Nakamura, Tomonori; Aomori, Tohru; Nishiba, H.; Shinozaki, T.; Yanagawa, T.; Takagishi, K.; Watanabe, H.; Okada, Y.; Nakamura, K.; Horiuchi, R.; Yamamoto, Koujirou.

In: Journal of Chemotherapy, Vol. 22, No. 3, 06.2010, p. 186-190.

Research output: Contribution to journalArticle

Fujita, Y, Nakamura, T, Aomori, T, Nishiba, H, Shinozaki, T, Yanagawa, T, Takagishi, K, Watanabe, H, Okada, Y, Nakamura, K, Horiuchi, R & Yamamoto, K 2010, 'Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma', Journal of Chemotherapy, vol. 22, no. 3, pp. 186-190.
Fujita, Y. ; Nakamura, Tomonori ; Aomori, Tohru ; Nishiba, H. ; Shinozaki, T. ; Yanagawa, T. ; Takagishi, K. ; Watanabe, H. ; Okada, Y. ; Nakamura, K. ; Horiuchi, R. ; Yamamoto, Koujirou. / Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma. In: Journal of Chemotherapy. 2010 ; Vol. 22, No. 3. pp. 186-190.
@article{95684c1af4f14b1cbc4a570178b7231e,
title = "Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma",
abstract = "Individualization of high-dose methotrexate (MTX) dosing is important to achieve therapeutic levels (700-1,000 μM) for osteosarcoma. Therefore we developed a pharmacokinetically (PK) individualized dosage regimen to maintain MTX concentrations of 700 μM (1 h bolus followed by 5 h maintenance infusion) and evaluated its safety and efficacy. Loading and maintenance doses were calculated by the PK parameters based on 2-compartment model analysis. Thirty-two courses of chemotherapy were performed in 9 patients with osteosarcoma. The maximum concentrations during maintenance infusion in 31 courses (97{\%}) were above 700 μM. Only 1 patient developed severe hepatotoxicity as adverse effect. Total body clearance of MTX decreased in 4 patients when weekly MTX chemotherapy was performed for 3 consecutive weeks. Although the clearance was changed, the average MTX concentrations were maintained at about 700 μM by the PK individualization. The 5-year survival rate was 77.8{\%} (7 of 9 patients), and all of them have survived for more than 9 years. This PK individualization is safe and useful for tailoring high-dose MTX therapy to achieve therapeutic levels.",
keywords = "5-Year survival rate, Methotrexate, Osteosarcoma, Pharmacokinetic individualization",
author = "Y. Fujita and Tomonori Nakamura and Tohru Aomori and H. Nishiba and T. Shinozaki and T. Yanagawa and K. Takagishi and H. Watanabe and Y. Okada and K. Nakamura and R. Horiuchi and Koujirou Yamamoto",
year = "2010",
month = "6",
language = "English",
volume = "22",
pages = "186--190",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma

AU - Fujita, Y.

AU - Nakamura, Tomonori

AU - Aomori, Tohru

AU - Nishiba, H.

AU - Shinozaki, T.

AU - Yanagawa, T.

AU - Takagishi, K.

AU - Watanabe, H.

AU - Okada, Y.

AU - Nakamura, K.

AU - Horiuchi, R.

AU - Yamamoto, Koujirou

PY - 2010/6

Y1 - 2010/6

N2 - Individualization of high-dose methotrexate (MTX) dosing is important to achieve therapeutic levels (700-1,000 μM) for osteosarcoma. Therefore we developed a pharmacokinetically (PK) individualized dosage regimen to maintain MTX concentrations of 700 μM (1 h bolus followed by 5 h maintenance infusion) and evaluated its safety and efficacy. Loading and maintenance doses were calculated by the PK parameters based on 2-compartment model analysis. Thirty-two courses of chemotherapy were performed in 9 patients with osteosarcoma. The maximum concentrations during maintenance infusion in 31 courses (97%) were above 700 μM. Only 1 patient developed severe hepatotoxicity as adverse effect. Total body clearance of MTX decreased in 4 patients when weekly MTX chemotherapy was performed for 3 consecutive weeks. Although the clearance was changed, the average MTX concentrations were maintained at about 700 μM by the PK individualization. The 5-year survival rate was 77.8% (7 of 9 patients), and all of them have survived for more than 9 years. This PK individualization is safe and useful for tailoring high-dose MTX therapy to achieve therapeutic levels.

AB - Individualization of high-dose methotrexate (MTX) dosing is important to achieve therapeutic levels (700-1,000 μM) for osteosarcoma. Therefore we developed a pharmacokinetically (PK) individualized dosage regimen to maintain MTX concentrations of 700 μM (1 h bolus followed by 5 h maintenance infusion) and evaluated its safety and efficacy. Loading and maintenance doses were calculated by the PK parameters based on 2-compartment model analysis. Thirty-two courses of chemotherapy were performed in 9 patients with osteosarcoma. The maximum concentrations during maintenance infusion in 31 courses (97%) were above 700 μM. Only 1 patient developed severe hepatotoxicity as adverse effect. Total body clearance of MTX decreased in 4 patients when weekly MTX chemotherapy was performed for 3 consecutive weeks. Although the clearance was changed, the average MTX concentrations were maintained at about 700 μM by the PK individualization. The 5-year survival rate was 77.8% (7 of 9 patients), and all of them have survived for more than 9 years. This PK individualization is safe and useful for tailoring high-dose MTX therapy to achieve therapeutic levels.

KW - 5-Year survival rate

KW - Methotrexate

KW - Osteosarcoma

KW - Pharmacokinetic individualization

UR - http://www.scopus.com/inward/record.url?scp=78650239053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650239053&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 186

EP - 190

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -